BCMA CAR-T

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

More Information

Trial Status
Active, Not Recruiting
Trial Phase
Phase 1
Enrollment
40 patients (estimated)
Sponsors
Arcellx, Inc., Kite, A Gilead Company
Collaborators
Arcellx, Inc.
Tags
CAR T Cell, B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1043
NCT Identifier
NCT04155749

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.